Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines

Karl S. Peggs*, Stephanie Verfuerth, Arnold Pizzey, Naeem Khan, Malcolm Guiver, Paul A. Moss, Stephen Mackinnon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

396 Citations (Scopus)

Abstract

Adoptive transfer of CMV-specific T cells offers the potential for reconstitution of viral immunity after allogeneic transplantation. However, the logistics of producing virus-specific T-cell clones has limited the application of cellular therapies. We treated 16 patients for CMV infection with polyclonal CMV-specific T-cell lines generated by short-term culture. Massive in-vivo expansions of CMV-specific cytotoxic T lymphocytes were observed, resulting in reconstitution of viral immunity. In eight cases antiviral drugs were not required, and subsequent episodes of reactivation occurred in only two patients. Our findings indicate that application of CMV-specific cell lines is both feasible and effective in a clinical environment.

Original languageEnglish
Pages (from-to)1375-1377
Number of pages3
JournalThe Lancet
Volume362
Issue number9393
DOIs
Publication statusPublished - 25 Oct 2003

Bibliographical note

Funding Information:
S Mackinnon is funded by the Leukaemia Research Fund (London, UK); K Peggs receives financial support from the Golden Charitable Trust (London, UK). The funding sources had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

Fingerprint

Dive into the research topics of 'Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines'. Together they form a unique fingerprint.

Cite this